臨床研究等提出・公開システム

Establishment of Japan high grade meningioma consortium for analysis of pathogenesis and development of new treatment strategy (JHMC)

JHMC registry study (JHMC)

Oya Soichi Soichi

Saitama Medical Center/University

Kawagoe, Saitama 350-8550, Japan

soichi@saitama-med.ac.jp

Soichi Oya

Saitama Medical Center/University

Kawagoe, Saitama 350-8550, Japan

+81-49-228-3671

soichi@saitama-med.ac.jp

Pending

June. 10, 2022

Observational

Patients with recurrent WHO grade 1 meningioma or WHO grade 2/3 meningioma who have undergone surgical resection at participating institutions from 2001 to the start of this study , who have completed the necessary medical examinations, whose residual specimens are stored, and who have already given consent for use in medical research in general, including genetic analysis, are included in this study.
The patients who have already given consent for the use of their specimens for genetic analysis and other medical research are also included in the study.
In addition, patients with newly diagnosed recurrent WHO grade 1 meningioma or WHO grade 2/3 meningioma who have undergone resection after the start of this study at the participating institutions are included if their consent for use in this study has been obtained at each institution for the remaining specimens after all necessary tests for treatment have been performed. Blood samples will also be collected from patients who fall into any of the above categories and who consent to have their blood samples collected.

Patients for whom consent for participation in the study described in "9. Methods of Obtaining Subjects' Understanding and Consent" in the research protocol can not be obtained are excluded.

Both

meningioma

recurrence, follow-up period

Feb. 22, 2022

Yes

Somatic mutation information and embryonic cell information in aggregated form, such as frequency in a population in which individuals are not identified, may be registered in public databases for the purpose of contributing to the elucidation of the causes of diseases and the establishment of treatments by providing genome data to many researchers. The data may be disclosed and shared with approved researchers after screening. The data may be made public and shared with researchers who have been screened and approved. Individual germ cell information may be released only to researchers who have been approved after consultation with other researchers.

none